Overview
uBiome began by inviting people to contribute samples and money to microbiome research. It later sold clinical tests through doctors and sought insurance reimbursement. Those models had different obligations: explaining microbial data to curious consumers did not establish the medical need, validity, or billing basis for a clinical test.[1][2]
The company ceased operations in 2019 after investigations and an unsuccessful restructuring. Civil and criminal proceedings followed. A September 2026 SEC update describes proposed civil judgments, subject to court approval, without admissions. It does not establish a criminal conviction.[3][4]
Founding Story
Jessica Richman, Zachary Apte, and Will Ludington founded uBiome in 2012. A launch interview at UCSF’s incubator records the original idea: let participants help generate questions and contribute samples. Ludington described citizen science as allowing people to “take part in scientific experiments.” Richman’s early pitch was curiosity about the organisms living in and on a person’s body.[1]
Apte also discussed opt-in research data and privacy protections. That ambition created a lasting responsibility for samples and information beyond the sale of a kit. Ludington left in 2013, according to UCSF’s later account. The subsequent SEC and criminal actions discussed here name Richman and Apte, not Ludington.[1][5]
Y Combinator’s August 2014 post identifies uBiome as S14. It reports a $351,193 Indiegogo campaign and $4.5 million from angel investors and Andreessen Horowitz. The early funding platform was Indiegogo; some later accounts incorrectly call it Kickstarter.[6]
Timeline
- 2012–2013: The team launched a crowdfunded citizen-science project and began selling consumer kits.[1][7]
- 2014: uBiome participated in YC’s summer batch.[6]
- 2018: A bankruptcy declaration later recorded a $59 million venture round and approximately 300 employees at that time.[7]
- 2019: Clinical products were suspended. Chapter 11 began September 4; on October 1, management requested conversion to liquidation.[7][3]
- 2020: Psomagen and Macrogen announced acquisition of key assets after a December 2019 closing.[8]
- 2021: The SEC and federal prosecutors announced actions against Richman and Apte.[9][2]
- 2026: The SEC announced proposed civil settlements. Final court approval and the criminal case’s disposition are not established in the checked sources.[4]
What They Built
The consumer service compared microbes identified in a submitted sample with other samples. Clinical products included SmartGut and SmartJane. Unlike the consumer kit, they were ordered through doctors and billed to insurance. Their positioning extended beyond exploratory research toward decisions about health.[2]
The workflow combined sample collection, laboratory sequencing, computational analysis, and a customer report. The bankruptcy declaration described a consumer Explorer kit sold for $89.99 and a separate clinical business. This distinction matters because laboratory processing, medical interpretation, authorization, and reimbursement are separate steps.[7]
The founders’ early language emphasized participation. Apte told the launch interviewer that customers could “contribute their samples to us.” Scaling that exchange required clear terms about what participants authorized and what the results could support.[1]
Market Position
Target Customers
uBiome first served people interested in learning about their microbial communities and participating in research. The clinical business added patients, ordering clinicians, and insurers. A patient’s interest in a report did not by itself establish that an insurer should pay for the test.
Market Size
A growing research field did not define a reimbursable clinical market. The relevant opportunity depended on an indicated use, valid evidence, clinician demand, and payment rules. No verified commercial market size for uBiome’s specific clinical offering is established here.
Competition
Microbiome research continued after uBiome closed. The important constraint was the quality and appropriate use of evidence. A 2025 international consensus statement reports limited evidence for routine clinical microbiome testing, discourages direct patient requests without clinical recommendation, and discourages testing providers from issuing post-test therapeutic advice. This is a professional consensus, not a finding about every individual assay or a blanket ban.[10]
Business Model
Consumer customers paid for a kit; the clinical business pursued insurance payments. The 2021 indictment alleged that problematic practices included repeat testing of archived samples, misleading information to ordering providers, and manipulated service dates. These are allegations in a criminal case, not findings of guilt in this report.[2]
Funding figures also need care. A contemporary headline announced an $83 million Series C.[11] The sworn bankruptcy declaration records a $59 million October 2018 round, following approximately $5 million in 2014 and $17 million in 2016. Its footnote separately describes $36.4 million of convertible notes later converted to equity. These measures should not be added without tracing overlap.[7]
The SEC’s 2021 complaint alleged that investors received a misleading picture of reimbursement-driven growth. Revenue already collected was therefore not sufficient evidence of a durable model if insurers could challenge it.[9]
Outcome and evolution
New management tried to preserve the consumer business through restructuring. The October 2019 company announcement said it could not reach agreement on bankruptcy financing and would cease operations and liquidate. This was a failed attempt to continue a narrower business, rather than a successful restructuring.[3]
Macrogen’s January 2020 announcement says the consortium paid $7.05 million for key assets, including patents, data described as anonymized, samples, and equipment. It dates closing to December 27, 2019. This buyer statement does not establish continuing original uBiome services or unrestricted permission for any later use of patient information.[8]
The SEC’s September 16, 2026 release provides the latest checked civil update. Richman and Apte consented, without admitting the allegations, to proposed judgments with three-year restrictions and $125,000 penalties each. The release expressly says court approval remained required. This civil development does not resolve the separate criminal case.[4]
Key Lessons
- Separate research from clinical claims. Interesting associations do not establish a validated diagnostic or useful treatment decision.
- Treat reimbursement as conditional. Track authorization, medical need, and documentation before treating collected payments as repeatable demand.
- Reconcile financing measures. An announced round, new cash, and converted notes can describe different amounts.
- Plan the data handoff. Participants’ information and samples need a clear stewardship plan if the company stops operating.
Sources
- UCSF Synapse — Original founder interview, January 2013
- DOJ — Indictment announcement, March 2021
- uBiome — Liquidation request and closure, October 2019
- SEC — Proposed civil settlements, September 2026
- UCSF Synapse — Founder history and Ludington departure
- Y Combinator — S14, crowdfunding and early financing, August 2014
- Bankruptcy court — Acting CEO declaration, September 2019
- Macrogen — Completed asset acquisition, January 2020
- SEC — Initial civil allegations, March 2021
- International consensus statement on microbiome testing, 2025
- TechCrunch — Announced 2018 financing